Larvol Delta - AltruBio-Announces-FDA-Clearance-of-IND-Application-for-Immune-Checkpoint-Enhancer-ALTB268-to-initiate-a-Phase-2-Clinical-Trial-for-the-Treatment-of-Ulcerative-Colitis

leiolizumab (ALTB-268) - AltruBio

https://www.globenewswire.com/news-release/2023/09/26/2749411/0/en/AltruBio-Announces-FDA-Clearance-of-IND-Application-for-Immune-Checkpoint-Enhancer-ALTB-268-to-initiate-a-Phase-2-Clinical-Trial-for-the-Treatment-of-Ulcerative-Colitis.html

Sep 26, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next